The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Genspera Receives Patent on Targeted Prostate Cancer Drugs

10-Jun-2013 | Source : | Visits : 9626
SAN ANTONIO, Texas - GenSpera Inc. announced in a press release that the United States Patent and Trademark Office (USPTO) issued patent 8,450,280 “Activation of Peptide Prodrugs by HK2.” The patent covers the composition of a series of prodrugs activated by HK2 to deliver a thapsigargin derivative selectively to prostate cancers. HK2 is an enzyme secreted by prostate cancer cells. A derivative of thapsigargin, 12ADT, is the active component of G-202, GenSpera’s lead drug candidate in Phase II clinical trials for liver cancer after sorafenib (Nexavar®) therapy.

“The issuance of this patent further strengthens our intellectual property position for targeted anti-cancer prodrugs and recognizes their unique applicability in treating prostate cancer,” commented GenSpera CEO, Craig Dionne, Ph.D. “It is important that we continue to expand and defend our thapsigargin prodrug research and development in areas of high unmet medical needs and commercial opportunities.”

GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor.

Related Articles